Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2019 11:59 ET | Source: Hemispherx Biopharma, Inc.

REPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference

OCALA, Fla., Jan. 24, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
January 23, 2019 00:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference

OCALA, Fla., Jan. 23, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
January 08, 2019 12:50 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center

OCALA, Fla., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
January 02, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

OCALA, Fla., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
December 26, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application ‘No Recent Stories’ Misinformation

OCALA, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) continues to work with Apple and other affected parties for a solution to correct Apple iOS12 Stocks...
December 19, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program

OCALA, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
December 17, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States

OCALA, Fla., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
December 12, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Issues Letter to Stockholders

OCALA, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to...
November 15, 2018 09:04 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results

OCALA, Fla., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the three and nine months ended September 30, 2018, and provides a...
October 29, 2018 18:39 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed

OCALA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...